---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004954"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:09:30.454861+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update

## Summary
- Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.
- European Patent Office granted patent for REQORSA + PD-1 antibodies to treat cancer.
- Acclaim-3 Phase 2 expansion: enrollment of first 25 patients for interim analysis expected by H1 2026; interim analysis in H2 2026.
- Phase 2 primary endpoint: 18-week progression-free survival rate; trial targets ~50 patients with ES-SCLC.

## SEC filing metadata
- accession: 0001437749-26-004954
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/0001437749-26-004954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004954
- JSON: https://secwatch.observer/filing/0001437749-26-004954.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.